Trials / Unknown
UnknownNCT01455649
Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults
A Prospective, Open-label, Controlled, Randomized Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After 90 to 150 Days After Kidney Transplantation in Adults, Maintaining Corticosteroid and Mycophenolate Sodium Compared to Patients Who Will Maintain the Use of Calcineurin Inhibitor
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Deise de Boni Monteiro de Carvalho · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the efficacy and safety in the use of everolimus, with its onset after 3 months of treatment with calcineurin inhibitor.
Detailed description
The patient who met the inclusion and exclusion criteria will be included in the study and randomized into two groups in the third month post transplant, they will be in use of tacrolimus, corticosteroids and Mycophenolate sodium. The group 1 will undergo a conversion from calcineurin inhibitor to Everolimus within 1 day (overnight), group 2 will be maintained with the initial immunosuppression. We will start Everolimus at 1 mg 2x/day and three days after the beginning we will adjust the dose by the serum levels, which will be kept in 6 to 10ng/dL. The doses of corticosteroids and Mycophenolate sodium will be retained. There will be performed renal biopsies at randomization and after 12 months. The glomerular filtration rate will be calculated monthly using the MDRD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | Group will switch calcineurin inhibitor to everolimus within 1 day (overnight). |
| DRUG | calcineurin inhibitor | Group will maintain their initial immunosuppression therapy with calcineurin inhibitor |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2011-10-20
- Last updated
- 2011-10-20
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT01455649. Inclusion in this directory is not an endorsement.